NEW YORK — Fujifilm Biotechnologies has been named a 2026 CDMO Leadership Award winner for Most Innovative CDMO (Biologics), recognition based on feedback from biopharma companies that have worked with the organization.
The annual awards, presented by Outsourced Pharma and Life Science Connect, are determined through sponsor evaluations gathered over the past 18 to 24 months, measuring performance across key outsourcing criteria.
The company, which provides contract development and manufacturing services for biologics, vaccines, and advanced therapies, was recognized for its continued investment in scientific research, process development, and collaboration with industry and academic partners.
“As part of Fujifilm’s 90-year heritage in healthcare innovation, our company continues to invest in science, analytics, and process development to support biologics, vaccines, and advanced therapies from early development through commercialization,” said Bernie Clark, vice president of global marketing at Fujifilm Biotechnologies. “Building on our legacy of innovation, we’ve recently launched ShunzymeX™, a technology platform that leverages a novel protease to simplify the purification process of complex biologics.”
The company said its focus on innovation has led to the development of new technologies aimed at improving efficiency in drug development and manufacturing.
“We are very grateful to our partners for their trust. Our success is built on collaboration, transparency, and a shared mission to be Partners for Life,” Clark added.
The awards were presented March 25 during DCAT Week in New York City, an annual gathering of companies involved in the global pharmaceutical and biotechnology industry. (Source: IANS)
